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Electrophysiologic testing was performed in 53 patients
with recurrent syncope that remained unexplained de-
spite a thorough neurologic and noninvasive cardiac
evaluation. Fifteen patients had no structural heart dis-
ease, 9 had mitral valve prolapse and 29 had structural
heart disease other than mitral valve prolapse. Nonsus-
tained ventricular tachycardia was induced in 15 pa-
tients (28%), sustained ventricular tachycardia was in-
duced in 9 (17%), ventricular fibrillation was induced
in 4 (8% ) and sinus node function was abnormal in 2
(4%) . Female sex and lack of structural heart disease
were independently associated with a negative electro-
physiologic study (p < 0.001). Patients with inducible
ventricular tachycardia or ventricular fibrillation were
treated with drugs selected on the basis of the results of
electropharmacologic testing. The recurrence rate of
syncope was 43% over a 31 ± 10 month period (mean
± standard deviation) of follow-up in patients with a
negative electrophysiologic study, 40% over a 22 ± 6
month period in patients with inducible nonsustained
Electrophysiologic testing has been reported (1,2) to be of
value in elucidating the cause of syncope in up to 56% of
patients with unexplained syncope. The majority of these
patients had organic heart disease, and the most common
abnormality demonstrated by electrophysiologic testing was
ventricular tachycardia. In a report (3) on patients who did
not have organic heart disease, electrophysiologic testing
was helpful in elucidating the cause of syncope in only 16%.
However, many of the patients in the latter study had either
presyncope or only one episode of syncope before evalua-
tion. The usefulness of electrophysiologic testing in patients
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ventricular tachycardia, 0% over a 30 ± 12 month pe-
riod in patients with inducible sustained ventricular
tachycardia and 25% over a 21 ± 10 month period in
patients with inducible ventricular fibrillation.
In patients with recurrent unexplained syncope
undergoing electrophysiologic testing, a potential cause
of syncope is least likely to be found in women without
structural heart disease. The results of programmed ven-
tricular stimulation must be interpreted with regard to
the method of induction of ventricular tachycardia and
the type of ventricular tachycardia induced. The excel-
lent response rate in patient s with inducible sustained
ventricular tachycardia whose therapy is guided by the
results of electropharmacologic testing suggests that sus-
tained ventricular tachycardia is a clinically significant
response. However, polymorphic nonsustained ventric-
ular tachycardia or ventricular fibrillation induced by
an aggressive stimulation protocol may be a nonspecific
response; syncope may recur despite treatment based on
results of electropharmacologic testing.
with recurrent syncope who do not have organic heart dis-
ease remains unclear.
Also unclear is the clinical signifi cance of nonsustained
ventricular tachycardia induced during eiectrophysiologic
testing in patients with unexplained syncope. Recent studies
(4- 6) demonstrated that nonsustained ventricular tachy-
cardia can be inducedfrequently in patients withouta history
of documented or suspected ventricular tachycardia, espe-
cially when an aggressive stimulation protocol is performed
in patients with organic heart disease, Therefore, there is
reason to question the clinical significance of nonsustained
ventricular tachycardia in patients with unexplained syncope.
The aim of this study was to clinically follow up patients
with recurrent syncope of unknown cause who had been
evaluated by electrophysiologic testing. We were particu-
larly interested in the results of clectrophysiologic testing
in patients with unexplained syncope who did not have
organic heart disease and the clinical significance of non-
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sustained ventricular tachycardia induced in patients with
syncope of an unknown cause.
Methods
Patient selection and evaluation. This prospective study
consisted of 53 patients (34 men and 19 women) who had
recurrent unexplained syncope. All had two or more epi-
sodes of complete but transient loss of consciousness with
loss of postural tone. All patients were evaluated by a neu-
rologist; an electroencephalogram was performed in 25 pa-
tients, computed tomography of the brain in 20 and a radio-
nuclide brain scan in 8. No patient was considered to have
a seizure disorder or other neurologic cause of syncope.
All patients were interviewed by one of us and underwent
a complete physical examination. Electrocardiography, two-
dimensional echocardiography, exercise treadmill testing and
at least 48 hours of ambulatory electrocardiographic mon-
itoring were performed in all patients. Congestive heart
failure was considered to be present if the patient had an S3
gallop on physical examination and left ventricular dys-
function on an echocardiogram. Ventricular premature de-
polarizations were graded as either occasional « 30/hour)
or frequent (> 30/hour). No patient had evidence of second
or third degree atrioventricular block, symptomatic supra-
ventricular tachycardia, ventricular tachycardia (more than
three consecutive ventricular premature depolarizations) or
sinus node dysfunction (heart rate < 45 beats/min or pauses
> 1.7 seconds).
Patients with the following potential causes of syncope
were excluded from this study: 1) bundle branch block or
high degree atrioventricular block, or both, 2) carotid sinus
hypersensitivity, 3) symptomatic postural hypotension, and
4) aortic stenosis or hypertrophic obstructive cardio-
myopathy. Also excluded were patients whose history in-
dicated classic vasovagal syncope. Eighteen of the patients
were among the subjects of an earlier report from our lab-
oratory (2).
Patient characteristics. The 53 patients were classified
into three groups based on the results of clinical evaluation.
Group I consisted of 15 patients with no evidence of
structural heart disease. Their mean age (± standard de-
viation) was 52 ± 20 years. They had had 5.7 ± 6.2
episodes of syncope over a 21.7 ± 30.4 month period.
Cardiac examination, electrocardiogram and exercise tread-
mill testing did not reveal any abnormalities in any patient.
Seven patients had no arrhythmia during ambulatory electro-
cardiographic monitoring, five had occasional and three had
frequent ventricular premature depolarizations.
Group II consisted of nine patients with mitral valve
prolapse diagnosed by physical examination and confirmed
by echocardiography. Their mean age was 42 ± 16 years.
They had had 6.9 ± 7.2 episodes of syncope over a 24.3
± 39 month period. The electrocardiogram showed no ab-
normalities in six patients and nonspecific ST-T wave ab-
normalities in three. No other structural heart disease was
present in these patients. Two patients had no arrhythmias
during ambulatory electrocardiographic monitoring, whereas
three had occasional and four had frequent ventricular pre-
mature depolarizations.
Group III consisted of 29 patients with structural heart
disease other than mitral valve prolapse. Their average age
was 66 ± 13 years. Seventeen patients had coronary artery
disease (15 of whom had a previous myocardial infarction),
7 had hypertension and left ventricular hypertrophy revealed
by the electrocardiogram and echocardiogram, 2 had non-
obstructive hypertrophic cardiomyopathy, 1 had congestive
cardiomyopathy, 1 had sarcoidosis (with presumed cardiac
involvement based on a rest thallium-201 myocardial scin-
tigram demonstrating a patchy distribution of perfusion de-
fects) and 1 had undergone aortic valve replacement for
aortic stenosis. This group had had an average of 5.6 ±
6.4 episodes of syncope over a 18.5 ± 29 month period.
The electrocardiogram showed pathologic Q waves in nine
patients, nonspecific ST-T wave abnormalities in seven, left
ventricular hypertrophy in seven and no abnormalities in
six. No arrhythmia occurred during ambulatory electrocar-
diographic monitoring in 5 patients, whereas 11 had oc-
casional and 11 had frequent ventricular premature depo-
larizations, and 2 had atrial fibrillation.
Electrophysiologic testing protocol. After obtaining
informed consent, patients were studied in the fasting, un-
medicated state. All antiarrhythmic drugs were discontinued
at least four half-lives before the study. Electrode catheters
were inserted percutaneously into a femoral vein and po-
sitioned in the high right atrium, across the tricuspid valve
for recording the His bundle electrogram, and in the right
ventricle. When necessary, an electrode catheter was in-
serted percutaneously into a femoral artery and positioned
against the left ventricular apex. Surface electrocardio-
graphic lead V1, I and III and intracardiac recordings from
the right atrium, His bundle region and right or left ventricle
were displayed simultaneously on an oscilloscope and re-
corded (Electronics for Medicine VR-12 recorder). Pacing
was performed with a programmable stimulator (Bloom Inc.)
at a current strength of 5 mA and a pulse duration of 2 ms.
The testing protocol was described in detail previously
(2). Briefly, the following variables were measured: atrio-
ventricular nodal and infranodal conduction times, sinus
node recovery time, sinoatrial conduction time by either the
extrastimulus (7) or overdrive technique (8), atrioventricular
conduction by incremental atrial pacing and atrioventricular
nodal refractoriness by the extrastimulus technique. At-
tempts were made to induce supraventricular tachycardia by
programmed atrial stimulation with one and two extrastimuli.
Burst ventricular pacing was performed at cycle lengths
ranging from 500 to 275 ms. In the first 20 patients entered
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into the study, right ventricular stimulation was performed
from the apex with one, two and three extrastimuli intro-
duced after five beats of ventricular drive at a cycle length
of 500 ms. In the next 33 patients, right ventricular stim-
ulation was performed from both the apex and the outflow
tract. and extrastimuli were introduced after five beats of
ventricular drive at cycle lengths of 500 and 400 ms. In 23
of 29 patients in whom sustained ventricular tachycardia
was not inducible with right ventricular stimulation. the
same stimulation protocol was performed from the left ven-
tricular apex. In six patients who did not have inducible
ventricular tachycardia with right ventricular stimulation,
left ventricular stimulation was not performed because of
the presence of a prosthetic aortic valve or severe athero-
sclerotic disease in the iliac arteries. In 17patients in whom
no ventricular tachycardia was induced. programmed stim-
ulation with one to three extrastimuli was repeated during
infusion of isoproterenol, titrated to maintain a heart rate
of 120 to 125 beats/min. Isoproterenol was not used in
patients who had angina pectoris. The protocol was dis-
continued after one induction of ventricular tachycardia or
ventricular fibrillation requiring electrical cardioversion, and
after two inductions of nonsustained ventricular tachycardia
or sustained ventricular tachycardia that could be terminated
with overdrive pacing.
Electropharmacologic testing protocol and treatment.
Electropharmacologic testing was performed in all patients
who had inducible ventricular tachycardia or ventricular
fibrillation. using a protocol described previously (9). When
the induction of ventricular tachycardia could not be sup-
pressed with a conventional antiarrhythmic drug, the patient
was treated with amiodarone and no further testing was
performed because the results of electropharmacologic test-
ing are not predictive of clinical response in patients treated
with amiodarone (l0-13). All patients who had inducible
sustained or nonsustained ventricular tachycardia or ven-
tricular fibrillation were treated chronically with antiar-
rhythmic drugs, except for two patients who refused treatment.
Empir ic drug therapy was defined as antiarrhythmic drug
therapy not based on the results of electropharmacologic
testing, either directed toward suppression of ventricular
premature depolarizations or started at the request of the
referring physician.
Sustained ventricular tachycardia was defined as ven-
tricular tachycardia that lasted at least 30 seconds or required
termination by overdrive pacing or electrical cardioversion.
Nonsustained ventricular tachycardia was defined as six or
more consecutive ventricular complexes, with spontaneous
termination within 30 seconds.
Follow-up. Patients were followed up at 3 month inter-
vals either by us or the referring physicians. Each patient
was questioned closely by one of us, either in person or by
telephone, regarding syncope recurrence. Sudden death was
defined as unexpected death from natural causes within
hour of the patient's collapse.
Statistical analysis. Values are expressed as mean x 1
standard deviation. Subgroups of patients were compared
using chi-square analysis or, when necessary, Fisher's exact
test. The independent effect of various clinical variables
(age, sex, history of prior myocardial infarction, presence
of frequent ventricular premature depolarizations. structural
heart disease. congestive heart failure or an abnormal elec-
trocardiogram) on the outcome of electrophysiologic testing
was assessed with a multiple logistics regression.
Results
Abnormalities demonstrated by electrophysiologic
testing. Among the 15 patients without structural heart dis-
ease (Group 1), no abnormalities were found during elec-
trophysiologic testing in 12 patients (80%), whereas non-
sustained ventricular tachycardia was induced in 3 (20%).
Sustained ventricular tachycardia or ventricular fibrillation
was not induced in any patient.
Among the nine pati ents who had mitral valve prolapse
(Group /1) , no abnormalities were found in three patients
(33%). nonsustained ventricular tachycardia was induced in
three (33%), sustained ventricular tachycardia was induced
in one ( II % ) and ventricular fibrill ation was induced in two
(22o/c ).
Among the 29 patients with structural heart disease other
than mitral valve prolapse (Group lll t, no abnormalities
were found in 8 patients (28%), nonsustained ventricular
tachycardia was induced in 9 (31% ), sustained ventricular
tachycardia was induced in 8 (28%), ventricular fibrillation
was induced in 2 (7%). I patient had a markedly prolonged
sinus node recovery time (3.8 seconds) and I had sinoatrial
entrance block.
A comparison of the three groups of patients showed that
a negative electrophysiologic study was found more com-
monly in patients without structural heart disease than in
the other two groups (probability [pI < 0.05). There was
no significant difference among the three groups in the prev-
alence of inducible nonsustained ventricular tachycardia.
Sustained ventricular tachycardia and ventricular fibrill ation
were induced more commonly in patients with structural
heart disease other than mitral valve prolapse compared with
patients without structural heart disease (p < 0.05).
Characteristics of induced ventricular tachycardia.
Nonsustained ventricular tachycardia was induced in a total
of 15 patients. The method of induction consisted of right
ventricular stimulation with two extrastimuli in 1 patient
and with three extrastimuli in 12; in 2 patients. left ven-
tricular stimulation with three extrastimuli was required to
induce ventricular tachycardia (during isoproterenol infu-
sion in I). The mean duration of nonsustained ventricular
tachycardia was 19 ::!: 14 beats/min and the cycle length
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was 209 ± 34 ms. The ventricular tachycardia had a po-
lymorphous configuration in II patients, a right bundle branch
block configuration in 3 and a left bundle branch block
configuration in 1.
Sustained ventricular tachycardia was induced in nine
patients (Table J). It was induced by right ventricular burst
pacing in one patient and by right ventricular stimulation
with three extrastimuli in six patients. Left ventricularstim-
ulation with three extrastimuli was required to induce ven-
tricular tachycardia in two patients. The mean ventricular
tachycardia cycle length was 261 ± 4S ms. The ventricular
tachycardia had a right bundle branch block configuration
in seven patients, a left bundle branch block configuration
in one and was polymorphous in one. The ventricular tachy-
cardia was terminated by ventricular overdrive pacing in
five patients and by electrical cardioversionin four patients.
Ventricular fibrillation was induced in three patients by
right ventricular stimulation with three extrastimuli and in
one patient by two extrastimuli. It was terminated by elec-
trical cardioversion in all four patients.
Clinical correlates of ventricular tachyca rdia indu-
cibility. Female sex and absence of structural heart disease
were independently associated with the lack of inducible
ventricular tachycardia (p < 0.001). Clinical variables that
had no independent effect on the outcome of electrophys-
iologic testing were age, ventricular premature depolari-
zation frequency during ambulatory electrocardiographic
monitoring. previous myocardial infarction, congestive heart
failure and an abnormal electrocardiogram.
Treatment and follow-up. The two patients with an
abnormality of sinus node function underwent implantation
of a permanent pacemaker. One patient has had no recur-
rence of syncope over a 20 month follow-up period and the
other (who had sinoatrial entrance block) has had one re-
currence of syncope during a 37 month follow-up period
(Fig. I).
Among the 23 patients who had no inducible ventricular
tachycardia or other abnormalities during electrophysio-
logic testing . the mean follow-up period has been 31 ± 10
months (Fig. 1). Ten patients were not treated with any
antiarrhythmic drug, 10 were treated empirically with a
conventional antiarrhythmic drug and 3 received a perma-
nent pacemaker at the request of the referring physician.
Seventy percent of untreated patients had no recurrence of
syncopeduring the follow-up period. Among the 10 patients
treated empirically with an antiarrhythmic drug. 40% had
no recurrence of syncope, but I died suddenly at 2 months
of follow-up . Two of three patients who received a pace-
maker have had recurrent syncope (with no evidence of
pacemaker malfunction).
Among the J5 patients in whom nonsustained ventricular
tachycardia was induced, the mean period of follow-up to
date is 22 ± 6 months (Fig. 2). Of the two patients who
refused treatment, one had recurrent syncope while being
monitored and was documented to be in sinus rhythm at the
timeof syncope;the other has had no recurrenceof syncope.
Thirteen patients were treated with drugs as guided by the
results of electropharmacologic testing (10 with conven-
tionalantiarrhythmic drugsand 3 witharniodarone); 8 (62%)
of the 13 patients have had no recurrence of syncope.
Among the nine patients in whom sustained ventricular
tachycardia was induced, the mean follow-up period is 30
± 12 months (Table I). All nine patients were treated with
antiarrhythmic drugs based on the results of electrophar-
macologic testing (five with conventional antiarrhythmic
drugs and four with amiodarone) . None has had recurrence
of syncope. This 100% response rate is significantly greater
than the 62% responserate in the patientswho had inducible
nonsustained ventricular tachycardia and who were treated
with antiarrhythmic drugs (p < 0.05).
The four patients who had inducible ventricular fibril-
lation were treated with conventional antiarrhythmic drugs
Table 1. Findings in Nine Men With Unexplained Syncope in Whom Sustained Ventricular Tachycardia Was Induced
Heart VTCL Months of Recurrence
Case Age (yr) Disease (lOS) Treatment Follow-Up ofSyncope
I 63 Sarcoid 250 Amiodarone 13
2 72 CAD 250 Amiodarone 13
3 50 Hypertensive 200 Procainamide 23
4 59 CCM 350 Amiodarone 25
5 71 CAD 210 Nadolol 28
6 67 MVP 270 Procamarrude and 33
quinidine
7 87 Hypertensive 290 Amiodarone 33
8 28 HCM 260 Quinidine and 45
propranolol
9 57 CAD 270 Procainamide and 47
disopyramide
CAD = coronary artery disease; CCM = congestive cardiomyopathy, CL = cycle length. HCM = hypertrophic cardiomyopathy; MVP = mitral
valve prolapse. VT = ventncular tachycardia.
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Figure 1. Treatment and follow-up of 25 patients with recurrent
syncopeand abnormal sinus node (SN) functionor no abnormality
demonstrated by electrophysiologic testing. AA = antiarrhythmic;
SO = sudden death.
Discussion
Role of electrophysiologic testing in patients with
unexplained syncope. Patients were included in this study
only if they had recurrent syncope that remained unex-
Figure 2. Treatment and follow-up of 28 patients with recurrent
syncope who had inducible ventricular tachycardia (VT) or ven-
tricular fibrillation (VF) during electrophysiologic testing. The lOOO/C
response rate in the patients with inducible sustained ventricular
tachycardia is significantly greater than the 62% response rate in
the patients who had inducible nonsustained ventricular tachy-
cardia and who were treated with antiarrhythmic (AA) drugs (p
< 0.05).
as guided by the results of electropharmacologic testing and
have been followed up for a 21 ± 10 month period. One
patient has had recurrent syncope but the others (75%) have
not.
In patients who had inducible ventricular tachycardia or
ventricular fibrillation. there was no significant difference
in the response to treatment comparing patients without
structural heart disease with those with mitral valve prolapse
and those with structural heart disease other than mitral valve
prolapse.
plained despite a careful neurologic and noninvasive cardiac
evaluation. In this highly selected group of patients, 66%
of those who had structural heart disease (including mitral
valve prolapse) and underwent electrophysiologic testing
were found to have inducible ventricular tachycardia or ven-
tricular fibrillation. In contrast, in the subgroup of patients
who did not have structural heart disease. only 20% were
found to have nonsustained ventricular tachycardia, which
is a potential cause of syncope. Therefore. the yield of
electrophysiologic testing appears to be considerably lower
in patients with unexplained syncope who do not have struc-
tural heart disease than in those who do have structural heart
disease. This is probably because serious arrhythmias and
conduction abnormalities occur less commonly in persons
without structural heart disease than in those who do have
structural heart disease.
Gulamhusein et al. (3) reported that electrophysiologic
testing revealed a potential cause of symptoms in only 12%
of 34 patients who had unexplained syncope or presyncope
and no structural heart disease; however. their ventricular
stimulation protocol included only right ventricular pacing
with up to two extrastimuli. Our data expand on their ob-
servations by including patients with recurrent syncope
undergoing an aggressive biventricular stimulation protocol
with three extrastimuli.
Clinical variables other than the presence or absence of
heart disease were of limited value in predicting the results
of electrophysiologic testing in patients with unexplained
syncope. The only other clinical variable independently as-
sociated with a negative electrophysiologic study was the
female sex. In the subset of five women without structural
heart disease, no abnormalities were demonstrated by elec-
trophysiologic testing. If this result is confirmed, it may
become appropriate to forego electrophysiologic testing in
such patients, given the very low yield.
Clinical significance of induced ventricular tachy-
cardia. Previous studies 0,2) reported inducible ventric-
ular tachycardia in 50 to 53% of patients with unexplained
syncope; however. no distinction was drawn between the
clinical value of nonsustained and sustained ventricular
tachycardia induced during electrophysiologic testing. Our
results suggest that this distinction may be quite important.
The clinical value of inducible sustained ventricular tachy-
cardia appears to be extremely high. with no recurrence of
syncope in patients treated with antiarrhythmic drugs di-
rected against ventricular tachycardia. On the other hand,
in patients who had inducible nonsustained ventricular
tachycardia, only 62% of patients remained free of syncope
despite drug treatment administered on the basis of results
from electropharmacologic testing.
Induction of nonsustained ventricular tachycardia or
ventricular fibrillation in some patients in this study may
have been a laboratory artifact unrelated to syncope. The
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this study and that of DiMarco et al. (1), a patient who had
inducible nonsustained ventricular tachycardia had no re-
currence of syncope despite lack of antiarrhythmic treat-
ment. 2) One patient in our series who had inducible non-
sustained ventricular tachycardia was documented to be in
sinus rhythm during an episode of syncope that occurred
after the electrophysiologic study. 3) Several reports (4-6)
documented that nonsustained ventricular tachycardia and
ventricular fibrillation can be induced by an aggressive stim-
ulation protocol in 37 to 45% of patients who have never
had documented or suspected ventricular tachycardia. This
nonsustained ventricular tachycardia or ventricular fibril-
lation usually occurs in patients with structural heart disease;
it is most often induced by three or more extrastimuli and
usually is rapid and polymorphic, as was the case in the
majority of episodes of nonsustained ventricular induced in
our patients. In contrast, sustained unimorphic ventricular
tachycardia is rarely inducible in patients who do not have
spontaneous ventricular tachycardia (4,5), even when a cur-
rent strength of 5 mA is used (6).
Therefore, the results of programmed ventricular stim-
ulation in patients with unexplained syncope should be in-
terpreted with consideration given to whether or not the
patient has heart disease, the method of ventricular tachy-
cardia induction and the type of ventricular tachycardia in-
duced. Sustained unimorphic ventricular tachycardia in-
duced in a patient with unexplained syncope is likely to
have clinical significance. However, rapid polymorphic
nonsustained ventricular tachycardia induced by three ex-
trastimuli in patients with structural heart disease may be a
nonspecific response.
Patients with a negative electrophysiologic study. A
striking finding of this study is the 70% spontaneous re-
mission rate among patients who had a negative electro-
physiologic study and received no treatment. A 44% spon-
taneous remission rate was reported by Gulamhusein et al.
(3) among patients with syncope or presyncope who had a
negative electrophysiologic study. The explanation for this
high spontaneous remission rate is unclear. The most likely
possibilities are: I) the apparent remission is due to spon-
taneous fluctuation in the frequency of syncope, and 2) many
of these patients may have a psychiatric or hysterical basis
for syncope and may benefit from a placebo effect associated
with undergoing an electrophysiologic study.
Ofnote is that patients with a negative electrophysiologic
study did not always have a benign prognosis. One patient
in this series with coronary artery disease and recurrent
syncope had no inducible ventricular tachycardia but died
suddenly 2 months later. Although the mechanism of sudden
death in this patient is not known, he may have had a
malignant ventricular arrhythmia due to abnormal auto-
maticity. Such arrhythmias are not inducible by pro-
grammed ventricular stimulation and cannot always be pro-
voked by isoproterenol. Alternatively, variables such as the
degree of myocardial ischemia may account for a fluctuating
propensity to have ventricular tachycardia or ventricular
fibrillation.
Role of pacemaker implantation. Gulamhusein et al.
(3) reported the resolution of symptoms of syncope or pre-
syncope in seven patients who had a negative electrophys-
iologic study and who received a permanent pacemaker.
However, the length of the follow-up period in these patients
was not noted. Their results must be interpreted with cau-
tion, given the high spontaneous remission rate noted earl-
ier. In the present series, two of three patients with a neg-
ative electrophysiologic study who received a permanent
pacemaker continued to have syncope. Therefore, we think
that it is unlikely that patients with recurrent unexplained
syncope and no bradyarrhythmia during ambulatory elec-
trophysiologic monitoring and a negative electrophysiologic
study will benefit from implantation of a permanent
pacemaker.
Abnormalities of sinus node function. An abnormality
of sinus node function was demonstrated by electrophysi-
ologic testing in only 2 of 53 patients in this study. The
incidence of sinus node dysfunction was low, probably be-
cause most patients with recurrent syncope due to the sick
sinus syndrome have some evidence of sinus node dys-
function during repeated ambulatory electrocardiographic
recordings (14,15). Such patients were specifically excluded
from this study.
The patient in this series, who had sinoatrial entrance
block has had recurrent syncope despite normal implanted
pacemaker function, indicating that her syncopal episodes
were not related to sinus node dysfunction. Therefore, the
clinical significance of an isolated abnormality in sinoatrial
conduction in patients with unexplained syncope remains
unclear.
Limitations. This study has two principal limitations:
1) There was no control group of patients with inducible
sustained ventricular tachycardia who were not treated with
antiarrhythmic drugs. Although the excellent response to
therapy in patients with inducible sustained ventricular
tachycardia was probably due to the correct identification
and proper treatment of the cause of syncope, the possibility
of spontaneous remissions in these patients cannot be ruled
out. 2) In patients who had induced ventricular tachycardia
or ventricular fibrillation and recurrent syncope despite treat-
ment, it is unclear whether syncope recurred because of
drug inefficacy or because the syncope was unrelated to
ventricular tachycardia. However, the lower recurrence rate
of syncope among the patients who had inducible sustained
ventricular tachycardia compared with nonsustained ven-
tricular tachycardia leads us to suspect that at least in some
patients the nonsustained ventricular tachycardia was a non-
specific finding that was unrelated to syncope.
Conclusions. Electrophysiologic testing is not equally
helpful in all subgroups of patients with recurrent unex-
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plained syncope. A potential cause of syncope is unlikely
to be demonstrated by electrophysiologic testing in women
who do not have structural heart disease. When patients
with bundle branch block or bradyarrhythmias occurring
during ambulatory electrocardiographic monitoring are
screened out, the most common abnormality demonstrated
by electrophysiologic testing is ventricular tachycardia.
However, the clinical significance of inducible ventricular
tachycardia in patients with unexplained syncope depends
on several factors: whether the patient has structural heart
disease, the method of induction of ventricular tachycardia
and the type of ventricular tachycardia induced (nonsus-
tained versus sustained; polymorphic versus unimorphic).
The results of programmed ventricular stimulation must be
interpreted with consideration of these factors. The finding
of sustained, unimorphic ventricular tachycardia is likely to
be clinically significant, with no recurrence of syncope dur-
ing antiarrhythmic drug therapy administered on the basis
of the results of electropharmacologic testing. However,
rapid polymorphic nonsustained ventricular tachycardia or
ventricular fibrillation induced by three extrastimuli in a
patient with structural heart disease may be a nonspecific
response, unrelated to syncope; a significant proportion of
such patients may have recurrent syncope despite treatment
guided by the results of electropharmocologic testing.
In patients with recurrent syncope who have a negative
electrophysiologic study, there is a high spontaneous re-
mission rate (70%). However, a negative electrophysiologic
study does not guarantee a benign prognosis. Our initial
experience suggests that there is no role for pacemaker ther-
apy in patients with recurrent syncope who have no abnor-
malities demonstrated during continuous electrocardio-
graphic monitoring or electrophysiologic testing.
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